IP Verse

Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or Agonist - EP3345607

The patent EP3345607 was granted to Ossifi MAB on Oct 26, 2022. The application was originally filed on Dec 21, 2007 under application number EP18157578A. The patent is currently recorded with a legal status of "Revoked".

EP3345607

OSSIFI MAB
Application Number
EP18157578A
Filing Date
Dec 21, 2007
Status
Revoked
Oct 3, 2025
Grant Date
Oct 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMGEN EUROPEJul 26, 2023GREINERADMISSIBLE
HIGHTONE MANAGEMENTJul 26, 2023GILL JENNINGS & EVERYADMISSIBLE
J A KEMPJul 26, 2023J A KEMPADMISSIBLE
UCB PHARMA UCB PHARMAJul 26, 2023MAIWALDADMISSIBLE

Patent Citations (71) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20060508701-
DESCRIPTIONUS20060613658-
DESCRIPTIONUS2002169122
DESCRIPTIONUS2002187104
DESCRIPTIONUS2004009535
DESCRIPTIONUS2004023356
DESCRIPTIONUS2004235728
DESCRIPTIONUS2005255604
DESCRIPTIONUS2006165799
DESCRIPTIONUS2006177475
DESCRIPTIONUS2006178752
DESCRIPTIONUS2006188542
DESCRIPTIONUS2006188544
DESCRIPTIONUS2006198863
DESCRIPTIONUS2006204542
DESCRIPTIONUS2006252724
DESCRIPTIONUS2007172479
DESCRIPTIONUS4631211
DESCRIPTIONUS4816567
DESCRIPTIONUS4935496
DESCRIPTIONUS4946778
DESCRIPTIONUS5010175
DESCRIPTIONUS5298852
DESCRIPTIONUS5324819
DESCRIPTIONUS5344654
DESCRIPTIONUS5468845
DESCRIPTIONUS5502167
DESCRIPTIONUS5530101
DESCRIPTIONUS5558864
DESCRIPTIONUS5565332
DESCRIPTIONUS5585089
DESCRIPTIONUS5639641
DESCRIPTIONUS5656593
DESCRIPTIONUS5693493
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5698417
DESCRIPTIONUS5705154
DESCRIPTIONUS5733743
DESCRIPTIONUS5750078
DESCRIPTIONUS5770403
DESCRIPTIONUS5939039
DESCRIPTIONUS6190880
DESCRIPTIONUS6395511
DESCRIPTIONUS6426332
DESCRIPTIONUS6489445
DESCRIPTIONUS6949251
DESCRIPTIONUS7189263
DESCRIPTIONWO9406416
OPPOSITIONEP1133558
OPPOSITIONEP2139507
OPPOSITIONEP2144613
OPPOSITIONEP2586796
OPPOSITIONUS2004009535
OPPOSITIONUS2004235728
OPPOSITIONUS2006030523
OPPOSITIONUS2007292444
OPPOSITIONWO0032773
OPPOSITIONWO03106657
OPPOSITIONWO2005003158
OPPOSITIONWO2005014650
OPPOSITIONWO2006119062
OPPOSITIONWO2006119107
OPPOSITIONWO2008133618
OPPOSITIONWO2009039175
OTHERUS2004009535
OTHERUS2004235728
SEARCHEP2144613
SEARCHEP2586796
SEARCHUS2004009535
SEARCHUS2004235728

Non-Patent Literature (NPL) Citations (98) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADAMS et al., Cancer Res., (19930000), vol. 53, page 4026-
DESCRIPTION- ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410-
DESCRIPTION- ALTSCHUL et al., Nuc. Acids Res., (19770000), vol. 25, pages 3389 - 3402-
DESCRIPTION- ASKEW et al., J. Am. Chem. Soc. Ill, (19890000), pages 1082 - 1090-
DESCRIPTION- BARBAS, C. F. et al., Proc Natl Acad Sci USA, (19910000), vol. 88, pages 7978 - 7982-
DESCRIPTION- BIOCCA S. et al., Biochem and Biophys Res Comm, (19930000), vol. 197, pages 422 - 427-
DESCRIPTION- CLACKSON, T. et al., Nature, (19910000), vol. 352, pages 624 - 628-
DESCRIPTION- CWIRLA et al., Proc. Natl. Acad. Sci., (19900000), vol. 87, pages 6378 - 6382-
DESCRIPTION- DEVLIN et al., Science, (19900000), vol. 49, pages 404 - 406-
DESCRIPTION- ELLIES et al., JBMR, (20061100), vol. 21, no. 11, pages 1738 - 49-
DESCRIPTION- FODOR et al., Science, (19910000), vol. 251, pages 767 - 773-
DESCRIPTION- FURKA et al., 14th International Congress of Biochemistry, (19880000), vol. #5-
DESCRIPTION- FURKA, Int. J. Peptide Protein Res., (19910000), vol. 37, pages 487 - 493-
DESCRIPTION- GEYSEN et al., J. Immunologic Method, (19870000), vol. 102, pages 259 - 274-
DESCRIPTION- GEYSEN et al., Molecular Immunology, (19860000), vol. 23, pages 709 - 715-
DESCRIPTION- GRUBER et al., J Immunol, (19940000), page 5368-
DESCRIPTION- HENIKOFF; HENIKOFF, Proc. Natl. Acad. Sci. USA, (19890000), vol. 89, page 10915-
DESCRIPTION- HU et al., Cancer Res., (19960000), vol. 56, page 3055-
DESCRIPTION- HUSE et al., Science, (19890000), vol. 246, page 1276-
DESCRIPTION- HUSE et al., Science, (19890000), vol. 246, pages 1275 - 1281-
DESCRIPTION- JONES et al., Nature, (19860000), vol. 321, no. 6069, pages 522 - 525-
DESCRIPTION- JONES et al., Nature, (19860000), vol. 321, pages 522 - 525-
DESCRIPTION- KARLIN; ALTSCHUL, Proc. Nat'l. Acad. Sci. USA, (19930000), vol. 90, pages 5873 - 5787-
DESCRIPTION- KEMP et al., J. Org. Chem., (19810000), vol. 46, pages 5140 - 5143-
DESCRIPTION- KONIECZNY et al., Haematologia, (19810000), vol. 14, no. l, pages 95 - 99-
DESCRIPTION- KOSTELNY et al., J Immunol, (19920000), vol. 148, page 1547-
DESCRIPTION- LEWIS; DEAN, Proc. R. Soc. Lond., (19890000), vol. 236, pages 25 - 140,141-162-
DESCRIPTION- MCCARTNEY et al., Protein Eng., (19950000), vol. 8, page 301-
DESCRIPTION- MCKINALY; ROSSMANN, Annu. Rev. Pharmacol. Toxiciol., (19890000), vol. 29, pages 111 - 122-
DESCRIPTION- MHASHILKAR, A. M. et al., EMBO J, (19950000), vol. 14, pages 1542 - 1551-
DESCRIPTION- MORRISON et al., Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, no. 21, pages 6851 - 6855-
DESCRIPTION- NEEDLEMAN; WUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443-
DESCRIPTION- PACK; PLUCKTHUN, Biochemistry, (19920000), vol. 31, page 1579-
DESCRIPTION- PEARSON; LIPMAN, Proc. Nat'l. Acad. Sci. USA, (19880000), vol. 85, page 2444-
DESCRIPTION- PERRY; DAVIES, OSAR: Quantitative Structure-Activity Relationships in Drug Design, Alan R. Liss, Inc., (19890000), pages 189 - 193-
DESCRIPTION- PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596-
DESCRIPTION- RICHARDSON J. H. et al., Proc Natl Acad Sci USA, (19950000), vol. 92, pages 3137 - 3141-
DESCRIPTION- RIECHMANN et al., Nature, (19880000), vol. 332, no. 6162, pages 323 - 327-
DESCRIPTION- RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327-
DESCRIPTION- RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329-
DESCRIPTION- RIPKA, New Scientist, (19880616), pages 54 - 57-
DESCRIPTION- ROTIVINEN, Acta Pharmaceutica Fennica, (19880000), vol. 97, pages 159 - 166-
DESCRIPTION- SCATCHARD, Ann. NY Acad. Sci., (19490000), vol. 51, pages 660 - 72-
DESCRIPTION- SCOTT; SMITH, Science, (19900000), vol. 249, pages 386 - 390-
DESCRIPTION- SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482-
DESCRIPTION- VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536-
DESCRIPTION- WARD et al., Nature, (19890000), vol. 341, pages 544 - 546-
DESCRIPTION- WINTER; HARRIS, Immunol. Today, (19930000), vol. 14, pages 243 - 246-
DESCRIPTION- YANAGITA, "Modulator of bone morphogenic protein activity in the progression of kidney diseases", Kidney Int., (20060000), vol. 70, no. 6, pages 989 - 93, XP009136809-
DESCRIPTION- ZHU et al., Protein Sci, (19970000), vol. 6, page 781-
DESCRIPTION- YANAGITA, "USAG-l: a bone morphogenic protein antagonist abundantly expressed in the kidney", Biochem. Biophys. Res. Commun., (20040000), vol. 316, no. 2, doi:doi:10.1016/j.bbrc.2004.02.075, pages 490 - 500, XP004495910
DESCRIPTION- YANAGITA, "BMP antagonists: their roles in development and involvement in pathophysiology", Cytokine Growth Factor Rev., (20050000), vol. 16, no. 3, doi:doi:10.1016/j.cytogfr.2005.02.007, pages 309 - 17, XP004964511
DESCRIPTION- YANAGITA, "Uterine sensitization-associated gene-1 (USA G-1), a novel antagonist expressed in the kidney, accelerates tubular injury", J. Clin. Invest., (20050000), vol. 116, no. 1, doi:doi:10.1172/JCI25445, pages 70 - 9, XP003020472
OPPOSITION- Anonymous, "Amgen Presents Denosumab and Sclerostin Antibody Data at American Society for Bone and Mineral Research Annual Meeting; Data Suggest the Potential for Targeting the Key Proteins, RANK Ligand and Sclerostin, for Bone Loss Conditions", Amgen, (20060919), pages 1 - 8, XP093094884-
OPPOSITION- Anonymous, "Indication for EVENITY® • (romosozumab-aqqg)", Amgen Inc., (20230101), pages 1 - 6, Amgen Inc., URL: https://www.pi.amgen.com/, (20240408), XP093148737-
OPPOSITION- Anonymous, "Osteoporosis and Low Bone Mass What Is the Difference and What Can I Do?", (20200601), pages 1 - 2, New York State Osteoporosis Prevention and Education Program (NYSOPEP), URL: https://www.health.ny.gov/publications/1986.pdf, (20231025), XP093094809-
OPPOSITION- Anonymous, "The Frequency of Bone Disease", Bone Health and Osteoporosis A Report of the Surgeon General Department of Health and Human Services, (20040101), pages 77 - 77, XP093094822-
OPPOSITION- Beers Mark H, Robert S Porter , Thomas V Jones , Justin L Kaplan , Michael Berkwits, "Osteoporosis ", Beers Mark H, Robert S Porter , Thomas V Jones , Justin L Kaplan , Michael Berkwits, Beers Mark H, Robert S Porter , Thomas V Jones , Justin L Kaplan , Michael Berkwits, The Merck manual of Diagnosis and Therapy, New Jersey USA, Merck Research Laboratories , (20060101), pages 305 - 308, XP093094913-
OPPOSITION- Bilezikian John P, Mishaela R. Rubin, "Combination/Sequential Therapies for Anabolic and Antiresorptive Skeletal Agents for Osteoporosis ", Current Osteoporosis Reports, (20060301), vol. 4, pages 5 - 13, XP093094558-
OPPOSITION- Ema, "EVENITY 105 mg solution for injection in pre-filled pen. EVENITY 105 mg solution for injection in pre-filled syringe ", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20220101), pages 1 - 66, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/documents/product-information/evenity-epar-product-information_en.pdf, (20240408), XP093148735-
OPPOSITION- Finkelstein Joel S, Annmarie Hayes, Joy L. Hunzelman,Jason J. Wyland,Hang Lee, Robert M. Neer, "The Effects ofParathyroid Hormone, Alendronate, or Both in Men with Osteoporosis ", New England Journal of Medicine, (20030925), vol. 349, no. 13, pages 1216 - 1226, XP093094762-
OPPOSITION- Geisslinger Gerd, Sabine Menzel, Thomas Gudermann, Burkhard Hinz, Peter Ruth, "Die Calciumhomöostase beeinflussende Mormone von Schilddrüse, Nebenschilddrüsen und Nieren", Mutschler Arzneimittelwirkungen Pharmakologie - Klinische Pharmakologie - Toxikologie, (20080101), pages 395 - 401, ISBN 978-3-8047-3663-4, XP093094899-
OPPOSITION- Kenneth ES Poole , Jonathan Reeve, "Parathyroid hormone - a bone anabolic and catabolic agent", Current Opinion in Pharmacology, NL , (20051201), vol. 5, no. 6, ISSN 1471-4892, pages 612 - 617, XP027625470-
OPPOSITION- Mutschler Ernst, Gerd Geisslinger , Heyo K. Kroemer , Monika Schäfer-Korting, "Prophylaxe und Therapie der Osteoporose", Mutschler Ernst, Gerd Geisslinger , Heyo K. Kroemer , Monika Schäfer-Korting, Mutschler Ernst, Gerd Geisslinger , Heyo K. Kroemer , Monika Schäfer-Korting, Mutschler Arzneimittelwirkungen Lehrbuch der Pharmakologie und Toxikologie, (20010101), pages 395 - 396, XP093094909-
OPPOSITION- Office Of The Surgeon General (us), "Chapter 9: PREVENTION AND TREATMENT FOR THOSE WHO HAVE BONE DISEASES", Bone Health and Osteoporosis: A Report of the Surgeon General., (20040101), pages 218 - 253, XP093148733-
OPPOSITION- Ominsky M; Stouch B; Doellgast G; Gong L; Cao J; Gao Y; Tipton B; Haldankar R; Winters A; Chen Q; Graham K; Zhou L; Hale M; Henry A; Lightwood D; Moore A; Popplewell A; Robinson M; Vlasseros F; Jolette J; Smith S Y; Kostenuik P J; Simonet W S; Lacey D L; Paszty C, "Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength", Journal of Bone and Mineral Research, US , (20060919), vol. 21, no. Suppl. 1, ISSN 0884-0431, pages S44 - S44, XP009101515-
OPPOSITION- Poole, K.E. ; Reeve, J., "Parathyroid hormone - a bone anabolic and catabolic agent", Current Opinion in Pharmacology, NL , (20051201), vol. 5, no. 6, ISSN 1471-4892, pages 612 - 617, XP027625470-
OPPOSITION- R.L. van Bezooijen , S.E. Papapoulos, C.W.G.M. Lowik, "Bone morphogenetic proteins and their antagonists: The sclerostin paradigm", Journal of Endocrinological Investigation, IT , (20050101), vol. 28, no. 8, ISSN 0391-4097, pages 15 - 17, XP008078167-
OPPOSITION- SUNDEEP Khosla, B. Lawrence Riggs, "Concise review for primary-care physicians (Treatment options for osteoporous)", Mayo Clinic Proceedings, (19951001), vol. 70, pages 978 - 982, XP055566009-
OPPOSITION- SUNDEEP Khosla, B. Lawrence Riggs, "Concise review for primary-care physicians (Treatment options for osteoporous)", Mayo Clin Proc, (19950101), vol. 70, pages 978 - 982, XP055566009-
OPPOSITION- Mcclung Michael R, Brown Jacques P, Diez‐perez Adolfo, Resch Heinrich, Caminis John, Meisner Paul, Bolognese Michael A, Goemaere Stefan, Bone Henry G, Zanchetta Jose R, Maddox Judy, Bray Sarah, Grauer Andreas, "Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study", Journal of Bone and Mineral Research, US , (20180801), vol. 33, no. 8, doi:10.1002/jbmr.3452, ISSN 0884-0431, pages 1397 - 1406, XP093094565
OPPOSITION- Keller, H. Kneissel, M., "SOST is a target gene for PTH in bone", Bone, GB , (20050801), vol. 37, no. 2, doi:10.1016/j.bone.2005.03.018, ISSN 8756-3282, pages 148 - 158, XP004977226
OPPOSITION- Langdahl Bente L; Libanati Cesar; Crittenden Daria B; Bolognese Michael A; Brown Jacques P; Daizadeh Nadia S; Dokoupilova Eva; Engelke Klaus; Finkelstein Joel S; Genant Harry K; Goemaere Stefan; Hyldstrup Lars; Jodar-Gimeno Esteban; Keaveny Tony M; Kendler David; Lakatos Peter; Maddox Judy; Malouf Jorge; Massari Fabio E; Molina Jose Fernando; Ulla Maria Rosa; Grauer Andreas, "Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19000101), vol. 390, no. 10102, doi:10.1016/S0140-6736(17)31613-6, ISSN 0140-6736, pages 1585 - 1594, XP085205189
OPPOSITION- Khan Abdul-Wahab, Khan Aliya, "Anabolic Agents: A New Chapter in the Management of Osteoporosis", JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA,, CA , (20060201), vol. 28, no. 2, doi:10.1016/S1701-2163(16)32063-1, ISSN 1701-2163, pages 136 - 141, XP093094835
OPPOSITION- Black Dennis M, Bilezikian John P, Ensrud Kristine E, Greenspan Susan L, Palermo Lisa, Hue Trisha, Lang Thomas F, Mcgowan Joan A, Rosen Clifford J, "One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis", The New England journal of medicine, US , (20050811), vol. 353, no. 6, doi:10.1056/NEJMoa050336, ISSN 0028-4793, pages 555 - 565, XP093094886
OPPOSITION- Cosman Felicia, Crittenden Daria B., Adachi Jonathan D., Binkley Neil, Czerwinski Edward, Ferrari Serge, Hofbauer Lorenz C., Lau Edith, Lewiecki E. Michael, Miyauchi Akimitsu, Zerbini Cristiano A.F., Milmont Cassandra E., Chen Li, Maddox Judy, Meisner Paul D., Libanati Cesar, Grauer Andreas, "Romosozumab Treatment in Postmenopausal Women with Osteoporosis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20161020), vol. 375, no. 16, doi:10.1056/NEJMoa1607948, ISSN 0028-4793, pages 1532 - 1543, XP093148731
OPPOSITION- Kenneth G. Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C. Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D. Meisner, Andreas Grauer, "Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20171012), vol. 377, no. 15, doi:10.1056/NEJMoa1708322, ISSN 0028-4793, pages 1417 - 1427, XP055744517
OPPOSITION- Canalis Ernesto, Giustina Andrea, Bilezikian John P., "Mechanisms of Anabolic Therapies for Osteoporosis", The New England journal of medicine, US , (20070830), vol. 357, no. 9, doi:10.1056/NEJMra067395, ISSN 0028-4793, pages 905 - 916, XP093094847
OPPOSITION- Xiaofeng Li , Yazhou Zhang, Heeseog Kang, Wenzhong Liu, Peng Liu, Jianghong Zhang, Stephen E Harris, Dianqing Wu, "Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.", Journal of Biological Chemistry, US , (20050520), vol. 280, no. 20, doi:10.1074/jbc.M413274200, ISSN 0021-9258, pages 19883 - 19887, XP002495892
OPPOSITION- Russell R, Espina Belen, Hulley Philippa, "Bone biology and the pathogenesis of osteoporosis", Current opinion in Rheumatology, GB , (20060601), vol. 18 , doi:10.1097/01.bor.0000229521.95384.7d, ISSN 1040-8711, pages S3 - S10, XP093094789
OPPOSITION- Schipani Ernestina, Zallone Alberta, Strewler Gordon J, Pike J Wesley, Ferrari Serge, Jiang Yebin, Seeman Ego, "Meeting report from the 27th annual meeting of the American society for bone and mineral research", BoneKEy-Osteovision, (20060101), vol. 3, no. 1, doi:10.1138/20060196, pages 29 - 62, XP093094916
OPPOSITION- V. Krishnan, Henry Bryant, Ormond Macdougald, "Regulation of bone mass by Wnt signaling", Journal of Clinical Investigation, (20060501), vol. 116, no. 5, doi:10.1172/JCI28551, ISSN 0021-9738, pages 1202 - 1209, XP055088452
OPPOSITION- Baron Roland; Rawadi Georges, "Minireview: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton", Endocrinology, US , (20070601), vol. 148, no. 6, doi:10.1210/en.2007-0270, ISSN 0013-7227, pages 2635 - 2643, XP009090901
OPPOSITION- Anthony B. Hodsman, Douglas C. Bauer, David W. Dempster, Larry Dian, David A. Hanley, Steven T. Harris, David L. Kendler, Michael R. McClung, Paul D. Miller, Wojciech P. Olszynski, Eric Orwoll and Chui Kin Yuen, "Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use", Endocrine reviews, US , (20050801), vol. 26, no. 5, doi:10.1210/ER.2004-0006, ISSN 0163-769X, pages 688 - 703, XP002679420
OPPOSITION- Ott Susan M., "Editorial: Sclerostin and Wnt Signaling—The Pathway to Bone Strength", Journal of Clinical Endocrinology and Metabolism, US , (20051201), vol. 90, no. 12, doi:10.1210/jc.2005-2370, ISSN 0021-972X, pages 6741 - 6743, XP093094567
OPPOSITION- D. Shoback, "Update in Osteoporosis and Metabolic Bone Disorders", Journal of Clinical Endocrinology & Metabolism, (20070301), vol. 92, no. 3, doi:10.1210/jc.2007-0042, ISSN 0021972X, pages 747 - 753, XP055035204
OPPOSITION- Rittmaster Roger S, Bolognese Michael, Ettinger Mark P, Hanley David A, Hodsman Anthony B, Kendler David L, Rosen Clifford J, "Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate", Journal of Clinical Endocrinology and Metabolism, US , (20000601), vol. 85, no. 6, doi:10.1210/jc.85.6.2129, ISSN 0021-972X, pages 2129 - 2134, XP093094807
OPPOSITION- Clifford J Rosen , John P Bilezikian, "Clinical review 123: hot topic anabolic therapy for osteoporosis", Journal of Clinical Endocrinology and Metabolism, US , (20010301), vol. 86, no. 3, doi:10.1210/jc.86.3.957, ISSN 0021-972X, pages 957 - 964, XP002969214
OPPOSITION- J P Rosen C J , Bilezikian J P, "Clinical review 123: hot topic anabolic therapy for osteoporosis", Journal of Clinical Endocrinology and Metabolism, US , (20010301), vol. 86, no. 3, doi:10.1210/jc.86.3.957, ISSN 0021-972X, pages 957 - 964, XP002969214
OPPOSITION- K. Warmington, S Morony , I. Sarosi , J. Gong , P. Stephens , D. G. Winkler, M. K. Sutherland, J. A Latharn, H. Kirby, A. Moore, M. Robinson, P.J. Kostenuik, S. Simonet , D. L. Lacey , C. Paszty_, "Abstract 1217 Sclerostin Antagonism in Adult Rodents, via Monoclonal Antibody Mediated Blockade, Increases Bone Mineral Density and Implicates Sclerostin as a Key Regulator of Bone Mass During Adulthood", Journal of Bone and Mineral Research, US , (20041005), vol. 19, doi:10.1359/JBMR.0301211, ISSN 0884-0431, pages S56 - S57, XP009072609
OPPOSITION- Debra L Ellies , Beth Viviano, John McCarthy, Jean-Philippe Rey, Nobue Itasaki, Scott Saunders, Robb Krumlauf, "Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.", Journal of Bone and Mineral Research, Blackwell Science, Inc., US, US , (20061101), vol. 21, no. 11, doi:10.1359/JBMR.060810, ISSN 0884-0431, pages 1738 - 1749, XP002554008
OPPOSITION- Debra L Ellies, Beth Viviano, John McCarthy, Jean-Philippe Rey, Nobue Itasaki, Scott Saunders,Robb Krumlauf, "Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.", Journal of Bone and Mineral Research, US , (20061101), vol. 21, no. 11, doi:10.1359/JBMR.060810, ISSN 0884-0431, pages 1738 - 1749, XP002554008
OPPOSITION- LI XIAODONG ET AL, "Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.", Journal of Bone and Mineral Research, Blackwell Science, Inc., US, US , (20090401), vol. 24, no. 4, doi:10.1359/JBMR.081206, ISSN 0884-0431, pages 578 - 588, XP002594505
OPPOSITION- Grey Andrew, Reid Ian R, "Emerging and potential therapies for osteoporosis", Expert Opinion on Investigational Drugs, UK , (20050301), vol. 14, no. 3, doi:10.1517/13543784.14.3.265, ISSN 1354-3784, pages 265 - 278, XP093094557
OPPOSITION- Lewiecki E Michael, "RANK ligand inhibition with denosumab for the management of osteoporosis.", Expert opinion on biological therapy, UK , (20061001), vol. 6, no. 10, doi:10.1517/14712598.6.10.1041, ISSN 1744-7682, pages 1041 - 1050, XP009126652
OPPOSITION- Rawadi Georges, Roman-Roman Sergio, "Wnt signalling pathway: a new target for the treatment of osteoporosis", Expert Opinion on therapeutic targets, UK , (20051001), vol. 9, no. 5, doi:10.1517/14728222.9.5.1063, ISSN 1472-8222, pages 1063 - 1077, XP093229059
OPPOSITION- Camacho Pauline M, Armamento-Villareal Reina, Kleerekoper Michael, "Postmenopausal osteoporosis: an update on current and future therapeutic options", Expert review of endocrinology & metabolism, GB , (20070101), vol. 2, no. 1, doi:10.1586/17446651.2.1.79, ISSN 1744-6651, pages 79 - 90, XP093094855
OPPOSITION- Sian Yik Lim , Marcy B Bolster, "Profile of romosozumab and its potential in the management of osteoporosis", Development and Therapy, (20170101), vol. 11, doi:10.2147/DDDT.S127568, pages 1221 - 1231, XP055566021

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents